Clinically Both Effects of Weight and Glucose Variability by Oral Semaglutide (Rybelsus) for Younger Female Patient with Type 2 Diabetes (T2D)-Reference-Cited by-同舟云学术

Clinically Both Effects of Weight and Glucose Variability by Oral Semaglutide (Rybelsus) for Younger Female Patient with Type 2 Diabetes (T2D)

Published:2022-06-22 Issue: Volume: Page:11-14
ISSN:2638-812X
Container-title:Journal of Obesity and Diabetes
language:en
Short-container-title:JOD

Author:

Hiroshi Bando¹,Hisako Yamashita²,Yoshinobu Kato²,Katsunori Ogura²,Yoshikane Kato²,Setsuko Kanazawa²

Affiliation:

1. Tokushima University/Medical Research, Tokushima, Japan

2. Kanaiso Hospital, Tokushima, Japan

Abstract

Background: Obesity and Type 2 Diabetes (T2D) are crucial problems worldwide. Oral semaglutide (Rybelsus) was introduced to medical practice for Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA). Case presentation: The patient is 24-year-old female with obesity (BMI 39.3 kg/m2), T2D and fatty liver. Results: She started and increased Rybelsus from 3mg, 7mg to 14mg/day each 4 weeks. She showed significant efficacy for 4 months as HbA1c 6.3% to 5.6% and weight 107kg to 103kg, without Gastrointestinal Adverse Events (GIAEs). Discussion: Rybelsus is provided just after waking up, and kept >30 min fasting period. Longer fasting time may contribute current effect.

Publisher

Edelweiss Publications Inc

Subject

General Engineering

Reference37 articles.

1. Lobstein T and Jewell J. What is a "high" prevalence of obesity? Two rapid reviews and a proposed set of thresholds for classifying prevalence levels (2022) Obes Rev 23: e13363.

2. Howell NA and Booth GL. The weight of place: Built environment correlates of obesity and diabetes (2022) Endocr Rev 24: bnac005.

3. Nicolucci A and Maffeis C. The adolescent with obesity: what perspectives for treatment? (2022) Ital J Pediatr 48: 9. https://doi.org/10.1186/s13052-022-01205-w

4. World Health Organization (WHO). Obesity and overweight.

5. Liu Y and Luo X. New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation (2022) Front Med 16: 17-24. https://doi.org/10.1007/s11684-021-0873-2 .